Companies › Bioray Laboratories
2 active drug programs in 2 registered trials: 2 Phase 1; Hematology, Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BRL-201 CD19-targeted CAR-T cell therapy with PD-1 site-specific integration | CD19 | Phase 1 | Non-hodgkin Lymphoma,B Cell | Nov 2026 |
| BRL-101 CRISPR-Cas9 modified autologous CD34+ hematopoietic stem and progenitor cells with BCL11A | – | Phase 1 | Beta-Thalassemia | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05741359 | BRL-201 | Phase 1 | Non-hodgkin Lymphoma,B Cell | Oncology | Nov 2026 |
| NCT05577312 | BRL-101 | Phase 1 | Beta-Thalassemia | Hematology | Jul 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.